Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
The first White Castle in the far western United States opened at the Casino Royale Hotel & Casino on the Las Vegas Strip on January 27, 2015. This was the first expansion for White Castle into a region outside the Midwest and Northeast in 56 years. On the first day of business, demand for food was so great that the restaurant had to temporarily close for two hours to restock. White Castle Vice President Jamie Richardson said that the store sold 4,000 sliders per hour in its first 12 hours. He was not aware of any similar closing due to unexpected demand in White Castle's 94-year history. A second White Castle location opened in Las Vegas in September 2017 on Fremont Street, a third opened in Jean at the Terrible's Road House in October 2018, a fourth location on Paradise Road in December 2019, and a fifth location in Henderson in June 2022. The Royale Hotel and Henderson locations were closed on March 30, 2026. In September 2015, White Castle began to offer Veggie Sliders with dairy-free buns to provide a vegan option. In December 2015, White Castle announced that chief executive officer (CEO) E.W. "Bill" Ingram III would step down at the end of the year, but continue to be chairman of the board. His daughter, Lisa Ingram, then became the fourth CEO of the company. In 2018, White Castle began offering plant-based meat Impossible Burgers designed to closely mimic the flavor and texture of beef burgers. The first White Castle location in Arizona opened in Scottsdale on October 23, 2019. A second location opened in nearby Tempe on November 28, 2023.
=== Antibody-directed enzyme prodrug therapy === Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells. The clinical success of ADEPT treatments is limited.
== Pharmaceutical salmon calcitonin formulations == Calcitonin, as salmon calcitonin (sCT), is available in the pharmaceutical market as an injectable preparation for intravenous, intramuscular or subcutaneous application. Noninvasive sCT preparation as a nasal spray is commercially produced and received US FDA approval under the proprietary name Miacalcin® in 1975 for the treatment of postmenopausal osteoporosis. The bioavailability of Miacalcin® nasal spray relative to the injectable form is between 3% and 5%. Currently, a number of sCT oral preparations are under clinical trials and at least one of them has reached Phase III of clinical approval.
Sources: en.wikipedia.org
=== Vaso-occlusive crisis === Most people with sickle cell disease have intensely painful episodes called vaso-occlusive crises (VOC). However, the frequency, severity, and duration of these crises vary tremendously. In a VOC, the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries to the tissues, inflammation, and pain. Recurrent episodes may cause irreversible organ damage. The most common and obvious symptom of a VOC is pain, which may be felt anywhere in the body but most commonly in the limbs and back. The degree of pain varies from mild to severe. Home treatment options include bed rest and hydration, and pain control using over-the-counter medication such as paracetamol or ibuprofen. More severe cases may require prescription opioids such as codeine or morphine for pain control. In 2019, crizanlizumab, a monoclonal antibody targeting P-selectin, was approved in the United States to reduce the frequency of vaso-occlusive crisis in those 16 years and older. It had also been approved in the UK and the European Union. In both cases, authorisation was subsequently withdrawn because of poor evidence of its effectiveness.
=== Without a hydrogen on the α-carbon === All proteinogenic amino acids have at least one hydrogen on the α-carbon. Glycine has two hydrogens, and all others have one hydrogen and one side-chain. Replacement of the remaining hydrogen with a larger substituent, such as a methyl group, distorts the protein backbone. In some fungi α-aminoisobutyric acid is produced as a precursor to peptides, some of which exhibit antibiotic properties. This compound is similar to alanine, but possesses an additional methyl group on the α-carbon instead of a hydrogen. It is therefore achiral. Another compound similar to alanine without an α-hydrogen is dehydroalanine, which possesses a methylene sidechain. It is one of several naturally occurring dehydroamino acids.
=== Operational names === Most of the coalition states used various names for their operations and the war's operational phases. These are sometimes incorrectly used as the conflict's overall name, especially the US Desert Storm:
This is especially useful for the neuroscience research that requires both molecular labeling and electron microscopic imaging. In diagnostic biosensor applications nanobodies may be used prospectively as a tool. Due to their small size, they can be coupled more densely on biosensor surfaces. In addition to their advantage in targeting less accessible epitopes, their conformational stability also leads to higher resistance to surface regeneration conditions. After immobilizing single-domain antibodies on sensor surfaces sensing human prostate-specific antigen (hPSA) were tested. The nanobodies outperformed the classical antibodies in detecting clinical significant concentrations of hPSA. To increase the crystallization probability of a target molecule, nanobodies can be used as crystallization chaperones. As auxiliary proteins, they can reduce the conformational heterogeneity by binding and stabilizing just a subset of conformational states. They also can mask surfaces interfering with the crystallization while extending regions that form crystal contacts.
Sources: en.wikipedia.org
Mitragotri has invented many novel drug delivery technologies, especially in the fields of transdermal, oral and targeted systems. He invented techniques to deliver drugs transdermally using low-frequency ultrasound, pulsed microjet injector, high throughput skin experimentation, skin penetrating peptides and ionic liquids. He also invented intestinal patches and ionic liquids for oral delivery of proteins. Mitragotri also pioneered nanoparticle-enabled cell therapies which use drug-loaded nanoparticles that hitch a ride on red blood cells, monocytes and other circulatory cells for tissue-specific delivery. Mitragotri's technologies are used to develop next generation therapies against diabetes, cancer, psoriasis, hemorrhage, trauma and infections. Mitragotri has published over 400 research publications and is an inventor on over 300 patents/applications. His publications are cited over 81000 times with an h-index of 140. Mitragotri is a member of the US National Academy of Medicine and the US National Academy of Inventors. He is also a member of the US National Academy of Engineering since 2015 for the development, clinical translation, and commercialization of transdermal drug delivery systems. He is also an elected member of The World Academy of Science , American Academy of Arts & Sciences and Indian National Academy of Engineering. He is a co-founder of several companies that are developing products based on his inventions. He received his PhD in chemical engineering at MIT and BS in chemical engineering from the Institute of Chemical Technology.
==== Combined malonic and methylmalonic aciduria (CMAMMA) ==== In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, there is an altered composition of complex lipids as a result of impaired mitochondrial fatty acid synthesis (mtFAS), so for example the content of cardiolipins is strongly increased.
Now differences between the contemporary squid and octopus samples became very clear. In the octopus, broad bands of fibers passed across the plane of the tissue and were separated by equally broad bands arranged in a perpendicular direction. In the squid there were narrower but also relatively broad bundles arranged in the plane of the section, separated by thin partitions of perpendicular fibers. It seemed I had found a means to identify the mystery sample after all. I could distinguish between octopus and squid, and between them and mammals, which display a lacy network of connective tissue fibers. After 75 years, the moment of truth was at hand. Viewing section after section of the St. Augustine samples, we decided at once, and beyond any doubt, that the sample was not whale blubber. Further, the connective tissue pattern was that of broad bands in the plane of the section with equally broad bands arranged perpendicularly, a structure similar to, if not identical with, that in my octopus sample. The evidence appears unmistakable that the St. Augustine sea monster was in fact an octopus, but the implications are fantastic. Even though the sea presents us from time to time with strange and astonishing phenomena, the idea of a gigantic octopus, with arms 75 to 100 feet in length and about 18 inches in diameter at the base—a total spread of some 200 feet—is difficult to comprehend.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.